The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...
Kamada begins patient enrolment in an investigator-initiated clinical trial of Cytogam to prevent cytomegalovirus in kidney transplantation: Rehovot, Israel Thursday, November 6, ...
Live Science on MSN
Aging and inflammation may not go hand in hand, study suggests
Declining immune responsiveness with age may be driven by changes in immune cells — not by inflammation, as previously ...
The outbreak of the COVID-19 pandemic demonstrated the need to rapidly develop, produce and distribute large quantities of ...
News-Medical.Net on MSN
Purdue researchers develop 30-second vaccine quality tool
The outbreak of the COVID-19 pandemic demonstrated the need to rapidly develop, produce and distribute large quantities of new vaccines. A team of researchers at Purdue University and Merck & Co. Inc.
Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...
AZoLifeSciences on MSN
Light-Based Sensor Continuously Detects Vaccine Quality
A group of researchers from Purdue University and Merck & Co. Inc., referred to as Merck Sharp & Dohme Corp. in regions outside the U.S. and Canada, has recently unveiled a novel analytical tool that ...
In two oral presentations, data presented from post-hoc analyses evaluated serum uric acid (sUA) levels, joint exam findings, health-related quality-of-life (HRQOL) outcomes, and gout flares in the ...
GlobalData on MSN
Kamada enrols first subject in Cytogam trial for CMV infection
The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback